ARTL Company Profile and Key Details

Q: Who are the executives of ARTL?

Dr. Andrew Yates Ph.D.Senior Vice President & Chief Scientific OfficerDr. Steven D. ReichChief Medical OfficerMr. Jason H. BaybuttSenior Vice President of Fin.Mr. Gregory D. Gorgas M.B.A.Pres, Chief Executive Officer, Chief Financial Officer, Treasurer, Sec. & Director

NASDAQ : ARTL

Artelo Biosciences

$1.07

-0.05-4.46%

Open: 9:53 AM

60.16

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Artelo Biosciences, Inc. (ARTL) stock declined over -4.46%, trading at $1.07 on NASDAQ, down from the previous close of $1.12. The stock opened at $1.09, fluctuating between $1.04 and $1.09 in the recent session.

Stock Snapshot

1.12

Prev. Close

2.5M

Market Cap

1.04

Day Low

-0.05

P/E Ratio

-20.24

EPS (TTM)

-2.07

Cash Flow per Share

1.09

Open

2.33M

Number of Shares

1.09

Day High

99.37%

Free Float in %

4.94

Book Value

154.3K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 21, 2026	1.11	1.16	1.10	1.12	55.76K
Jul 20, 2026	1.16	1.16	1.12	1.12	68.32K
Jul 17, 2026	1.15	1.15	1.11	1.15	90.19K
Jul 16, 2026	1.13	1.14	1.07	1.14	469.77K
Jul 15, 2026	1.17	1.24	1.13	1.15	399.27K
Jul 14, 2026	1.04	1.18	1.03	1.16	268.9K
Jul 13, 2026	1.05	1.08	1.01	1.05	399.19K
Jul 10, 2026	1.02	1.12	1.02	1.08	250.68K
Jul 09, 2026	0.98	1.07	0.98	1.02	128.71K
Jul 08, 2026	1.00	1.04	0.96	1.00	156.33K
Jul 07, 2026	1.07	1.08	0.98	1.00	216.31K
Jul 06, 2026	1.11	1.12	1.08	1.09	114.83K
Jul 02, 2026	1.11	1.11	1.06	1.11	130.1K
Jul 01, 2026	1.14	1.14	1.04	1.10	672.32K
Jun 30, 2026	1.08	1.15	1.08	1.12	267.09K
Jun 29, 2026	1.14	1.18	1.03	1.10	760.57K
Jun 26, 2026	1.10	1.16	1.10	1.12	120K
Jun 25, 2026	1.16	1.19	1.12	1.16	124.55K
Jun 24, 2026	1.26	1.26	1.15	1.16	267.64K
Jun 23, 2026	1.23	1.29	1.21	1.26	250.59K

Contact Details

Solana Beach, CA 92075

United States

https://www.artelobio.com 858 925 7049

About Company

Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.

Stock Peers

ARGX

28.55+3.37%

argenx SE$874.74 REGN

3.04+0.45%

Regeneron Pharmaceuticals, Inc.$675.19 MDGL

11.1+2.07%

Madrigal Pharmaceuticals, Inc.$546.79 UTHR

6.49+1.23%

United Therapeutics Corporation$535.83 VRTX

1.5+0.31%

Vertex Pharmaceuticals Incorporated$482.00 KRYS

-0.16-0.05%

Krystal Biotech, Inc.$339.06 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

8.11+2.61%

BeOne Medicines AG$318.69 PRAX

13.44+4.41%

Praxis Precision Medicines, Inc.$317.87 LGND

11.48+3.90%

Ligand Pharmaceuticals Incorporated$305.47

Company Overview

Artelo Biosciences, Inc. (NASDAQ:ARTL) closed at $1.07 USD, losing -$0.05 (-4.46%) from the previous close of $1.12. The stock is currently mid-range between its 52-week high and low $0.96 and $49.32. With a market capitalization of about $2.50 million, Artelo Biosciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.11). Key stats such as the average daily volume over the past year has been around 1.17 million shares, volume is running light vs its 52-week average. Headquartered in Solana Beach, CA, Artelo Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gregory D. Gorgas, the company employs approximately 7 people and listed since June 21, 2019. Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system.

Technical Performance

ARTL has shown mixed momentum, gaining 18.57% over the past week and -60.38% over the past quarter, though year-to-date performance is up 36.07%. Short-term trend indicators are bullishly aligned (SMA20 -10.12%, SMA50 -17.19%, SMA200 -77.32%). The stock’s 14-day RSI is 41.44 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -95.66% below its high and over 12.73% above its low. Average 10-day trading volume of 250.20 thousand shares is below the 3-month average of 1.03 million, indicating normal recent market interest.

Valuation Metrics

Artelo Biosciences, Inc. trades at a P/E ratio of -0.12, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.13 suggesting the stock is closer to book value. The P/FCF stands at -0.33, also above market averages.

Dividend & Fair Value

Artelo Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.03. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Artelo Biosciences, Inc. generated EPS of -$15.98 over the past year. Five-year average earnings growth is 35.6%. The latest quarter delivered EPS of -$4.00. The next quarter is forecast at $nan. Next year's EPS is expected at $59.19. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $18.00. The high target offers 1507.14% upside. The low target suggests 1507.14% downside. The mean target is $18.00. This offers 1507.14% upside. Artelo Biosciences, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 14, 2026, missed forecasts by 412.82%. The prior quarter beat by 41.4%. Over the last six quarters, Apple has recorded several small beats. These include 58.11% in March 03, 2025.

Shareholding & Insider Activity

Artelo Biosciences, Inc. has 3.49 million shares outstanding. The public float is 2.17 million shares, elevated short interest at 5.62% of float. This equals 195.94 thousand shares. The short ratio is 0.67 days. Institutional investors hold 8.31% of the float. Insiders own 2.47%. LAPIN STEVEN B holds 195.66 thousand shares, CRAWFORD JOHN JOSEPH has 95.67 thousand shares and TATUM JAMES G has 9.59 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Artelo Biosciences has not generated any revenue. Returns are negative, with ROA at -48.35% and ROE at -50.89%.
On valuation metrics, Artelo Biosciences trades at a P/E of -0.12, P/S of 0.00 and P/B of 0.13. The current ratio is 1.79 and quick ratio is 1.79. Debt-to-equity is 0.11, supported by a cash flow-to-debt ratio of -11.29.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2022, Artelo Biosciences posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Operating income was - $10.29M (margin 0.0%). Net income was- $9.87M (EPS - $3.49).
The company ended the quarter with $17.53M in cash and short-term investments, a total debt of $63.00K, and net debt of - $6.83M. Total assets were $20.42M, with equity of $0.00. Financials further reflected weakness, with operating cash flow of - $8.01M, free cash flow of - $8.01M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Artelo Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 10.71%, with price expected at $1.24 by August 04, 2026, within a range of $1.19 to $1.29 3-Month Outlook: Projected rise of 103.57%, reaching $2.28 by October 19, 2026, with a range of $0.78 to $2.81. 1-Year Outlook: Projected loss of -86.61%, with price at $0.15 by July 21, 2027, within a range of $0.00 to $0.72.

Key Takeaways

Artelo Biosciences, Inc. (NASDAQ:ARTL) shares are up 36.07% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Artelo Biosciences, Inc. trading at a premium to the broader market with a P/E of -0.12. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.59, suggesting 1291.96% upside. Our AI forecast model points to short-term strength (10.71% over two weeks), a medium-term rise (103.57% over three months), and a longer-term loss (-86.61% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Artelo Biosciences, Inc. (ARTL) stock price?

Artelo Biosciences, Inc. (NASDAQ: ARTL) stock price is $1.07 in the last trading session. During the trading session, ARTL stock reached the peak price of $1.09 while $1.04 was the lowest point it dropped to. The percentage change in ARTL stock occurred in the recent session was -4.46% while the dollar amount for the price change in ARTL stock was - $0.05.

ARTL's industry and sector of operation?

The NASDAQ listed ARTL is part of Biotechnology industry that operates in the broader Healthcare sector. Artelo Biosciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ARTL?

Dr. Andrew Yates Ph.D.
Senior Vice President & Chief Scientific Officer
Dr. Steven D. Reich
Chief Medical Officer
Mr. Jason H. Baybutt
Senior Vice President of Fin.
Mr. Gregory D. Gorgas M.B.A.
Pres, Chief Executive Officer, Chief Financial Officer, Treasurer, Sec. & Director

How ARTL did perform over past 52-week?

ARTL's closing price is 16.55% higher than its 52-week low of $0.96 where as its distance from 52-week high of $49.32 is -97.73%.

How many employees does ARTL have?

Number of ARTL employees currently stands at 7.

Link for ARTL official website?

Official Website of ARTL is: https://www.artelobio.com

How do I contact ARTL?

ARTL could be contacted at phone 858 925 7049 and can also be accessed through its website. ARTL operates from 505 Lomas Santa Fe, Solana Beach, CA 92075, United States.

How many shares of ARTL are traded daily?

ARTL stock volume for the day was 154.3K shares. The average number of ARTL shares traded daily for last 3 months was 1.17M.

What is the market cap of ARTL currently?

The market value of ARTL currently stands at $2.50M with its latest stock price at $1.07 and 2.33M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	7
Beta	-0.11
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ARTL Company Profile and Key Details

Artelo Biosciences

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook

Valuation Metrics